Katie Mc Ginn
About Katie Mc Ginn
Katie McGinn is a seasoned professional in quality assurance with over two decades of experience in the pharmaceutical industry. She currently serves as Director of Quality Assurance at Bristol Myers Squibb and has previously held senior roles at Incyte and Cephalon, Inc.
Current Role at Mirati Therapeutics
Katie Mc Ginn serves as the Director of Quality Assurance at Mirati Therapeutics, a position she has held since 2022. Based in San Diego, California, she oversees quality assurance processes to ensure compliance with industry standards. Her role involves implementing quality systems and leading teams to maintain high-quality standards in pharmaceutical development.
Previous Experience at Incyte
Katie Mc Ginn worked at Incyte from 2015 to 2022, where she held multiple positions. She began as a Senior Manager in Quality Control for one year before advancing to Associate Director from 2016 to 2019, and then served as Director until 2022. Her tenure at Incyte involved significant contributions to quality assurance and control, reflecting her expertise in the pharmaceutical sector.
Background in Chemistry
Katie Mc Ginn has a strong academic background in chemistry, having earned a Bachelor of Science degree from The College of New Jersey from 1992 to 1996. This educational foundation supports her extensive experience in quality assurance and control, enabling her to effectively manage quality processes in the pharmaceutical industry.
Career Progression in Quality Assurance
Over her two-decade career in the pharmaceutical industry, Katie Mc Ginn has transitioned from roles in quality control to leadership positions in quality assurance. This progression demonstrates her commitment to the field and her ability to adapt and grow within various roles, enhancing her expertise in quality management.
Experience at Cephalon, Inc
Katie Mc Ginn worked at Cephalon, Inc as an Analytical Chemist from 2004 to 2011. Her seven years in this role provided her with substantial experience in analytical processes, which likely contributed to her subsequent expertise in quality assurance and control within the pharmaceutical industry.